

**INTERACTIVE CE WEBCAST: Register online today at [www.neuroscienceCME.com/CMW501](http://www.neuroscienceCME.com/CMW501)**

# Advances in the Treatment of Schizophrenia: New Approaches

Webcast with Live Q&A Segment  
**[www.neuroscienceCME.com/CMW501](http://www.neuroscienceCME.com/CMW501)**

Or listen by phone at 800.895.1713

**Premiering Tuesday, November 16, 2010, from 12:00 p.m.–1:30 p.m. ET**



## FACULTY INFORMATION

**Donald C. Goff, MD**  
 Professor of Psychiatry  
 Harvard Medical School  
 Director, Schizophrenia Program  
 Massachusetts General Hospital  
 Boston, MA

**Philip D. Harvey, PhD**  
 Professor of Psychiatry and Behavioral Sciences  
 University of Miami Miller School of Medicine  
 Miami, FL

## CREDIT INFORMATION

**CME Credit (Physicians):** CME Outfitters, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME Outfitters, LLC designates this Enduring material for a maximum of 1.5 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity.

**Note to Physician Assistants:** AAPA accepts Category I credit from AOACCME, Prescribed credit from AAFP, and AMA Category I CME credit for the PRA from organizations accredited by ACCME.

**CNE Credit (Nurses):** Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.

**CEP Credit (Psychologists):** CME Outfitters is approved by the American Psychological Association to sponsor continuing education for psychologists. CME Outfitters maintains responsibility for this program and its content. (1.5 CE credits)

**NASW Credit (Social Workers):** This program was approved by the National Association of Social Workers (provider #886407722) for 1.5 continuing education contact hours.

**CCMC Credit (Certified Case Managers):** This program has been approved for 1.5 hours by the Commission for Case Manager Certification (CCMC).

**CPE Credit (Pharmacists):** CME Outfitters, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs)

Universal Activity Number:  
 0376-0000-10-024-L01-P (live presentation)  
 0376-0000-10-024-H01-P (recorded programs)  
 Activity Type: knowledge-based

Post-tests, credit request forms, and activity evaluations can be completed online at [www.neuroscienceCME.com](http://www.neuroscienceCME.com) (click on the Testing/Certification link under the Activities tab—requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit [www.neuroscienceCME.com/technical.asp](http://www.neuroscienceCME.com/technical.asp). CE credit expires on November 16, 2011.

**Premiere webcast offers a LIVE Q&A segment and qualifies for live CE credit.**

Submit your questions directly to the faculty via phone or web.

Questions? Call CME Outfitters at **877.CME.PROS**.

This activity offers CE credit for:

- Physicians (CME)
  - Psychologists (CEP)
  - Case Managers (CCMC)
  - Nurses (CNE)
  - Social Workers (NASW)
  - Pharmacists (CPE)
- All other clinicians will either receive a CME Attendance Certificate or may choose any of the types of CE credit being offered.

Online archive will be offered until November 16, 2011.

## STATEMENT OF NEED

A critical component of recovery in schizophrenia is functional remission. Recovery requires effort on the part of patients and support from caregivers to bypass societal barriers and reach functional objectives. Clinicians must learn strategies to achieve functional remission, consistently measure functional change in their patients, and work with patients to raise the bar toward achieving functional remission. Clinicians must know specific distinctions in efficacies of antipsychotic agents.

As we increasingly broaden our treatment goals from an exclusive focus on effectiveness to improving quality of life, minimizing drug side effects and medical complications becomes a high priority of treatment. In addition, selection of an antipsychotic agent often involves a balance among optimal efficacy, safety, and tolerability for an individual patient.

This neuroscienceCME Webcast will address a comprehensive approach in the choice of antipsychotic agent and measurement of functioning in the treatment of schizophrenia. The activity will review the relationships among side effects, adherence, and medical morbidity. It will specifically address the side effect profiles of the new-generation agents while discussing strategies to minimize their side effects and medical risk.

## ACTIVITY GOAL

To distinguish benefits and risks of various pharmacological therapies in the treatment of schizophrenia and provide strategies for use in clinical practice to improve functional outcome and overall quality of life for patients affected by schizophrenia.

## LEARNING OBJECTIVES

At the end of this CE activity, participants should be able to:

- Distinguish among efficacy and effectiveness profiles of different antipsychotic agents to optimize treatment selection.
- Individualize treatment for patients with schizophrenia by balancing the relative experiences of each patient with side effects, medical morbidity, and medication adherence history.
- Implement strategies to measure functional change and integrate functional remission into treatment goals for patients with schizophrenia.

## TARGET AUDIENCE

Physicians, physician assistants, nurses, nurse practitioners, psychologists, pharmacists, social workers, certified case managers, and other healthcare professionals with an interest in schizophrenia.

## ACKNOWLEDGEMENT OF FINANCIAL SUPPORT

Supported by an educational grant from Dainippon Sumitomo Pharma America, Inc. On April 1, 2010, DSPA merged with Sepracor Inc., creating one, united North American operation for our parent company, Dainippon Sumitomo Pharma Co., Ltd.

\_\_\_\_\_ FAX completed form to **614.929.3600** \_\_\_\_\_

**YES! Register me for this evidence-based neuroscienceCME Webcast activity on November 16, 2010.**

I will participate online.  I will participate by phone.

**YES! Register me for the online archive.** (Participation details will be sent to you via email.)

Site Name: \_\_\_\_\_ # Participants: \_\_\_\_\_

Individual Name: \_\_\_\_\_ Degree: \_\_\_\_\_

Address: \_\_\_\_\_

City/State/ZIP: \_\_\_\_\_

Practice Setting:  Community Mental Health  State Mental Health  Primary Care  Private Practice  Other: \_\_\_\_\_ Phone: \_\_\_\_\_

Fax: \_\_\_\_\_ Email (required): \_\_\_\_\_

This continuing education activity is provided by

